Document is current
Any future updates will be listed below
-
Authors
Bailón, Lucia https://orcid.org/0000-0001-7277-9314
Llano, Anuska https://orcid.org/0000-0002-0133-9888
Cedeño, Samandhy https://orcid.org/0000-0001-8312-0208
Escribà, Tuixent https://orcid.org/0000-0001-9467-7802
Rosás-Umbert, Miriam https://orcid.org/0000-0002-2850-6586
Parera, Mariona
Casadellà, Maria https://orcid.org/0000-0002-4115-2305
Lopez, Miriam
Pérez, Francisco
Oriol-Tordera, Bruna https://orcid.org/0000-0002-2714-9097
Ruiz-Riol, Marta
Coll, Josep
Perez, Felix
Rivero, Àngel
Leselbaum, Anne R.
McGowan, Ian https://orcid.org/0000-0002-6470-8476
Sengupta, Devi
Wee, Edmund G.
Hanke, Tomáš https://orcid.org/0000-0002-6076-9546
Paredes, Roger https://orcid.org/0000-0002-6553-691X
Alarcón-Soto, Yovaninna https://orcid.org/0000-0002-9977-8634
Clotet, Bonaventura https://orcid.org/0000-0003-3232-4598
Noguera-Julian, Marc https://orcid.org/0000-0002-6194-1395
Brander, Christian https://orcid.org/0000-0002-0548-5778
Molto, Jose
Mothe, Beatriz https://orcid.org/0000-0001-9975-407X
,
Barriocanal, Ana María
Benet, Susana
Cobarsi, Patricia
Geleziunas, Romas
Leselbaum, Anne R.
Loste, Cora
Meulbroek, Michael
Miranda, Cristina
Muñoz, Jose
Naval, Jordi
Nieto, Aroa
Pujol, Ferran
Puig, Jordi
- License Information
-
More Information
Article History
Received: 3 November 2021
Accepted: 28 September 2022
First Online: 27 October 2022
Competing interests
: C.B., B.M. and A.L.L. are co-inventors of the HTI immunogen (patent application PCT/EP2013/051596). C.B., B.M. and I.M. are co-inventors of US patent application no. 62/935,519 and US patent application no. 62/851,546, which have relevance to the vaccine regimen used in this study. B.M. reports consultancy personal fees from AELIX Therapeutics SL, as well as speakers’ fees from Gilead, Janssen and ViiV Healthcare, outside the submitted work. C.B. is co-founder, CSO and shareholder of AELIX Therapeutics SL and serves as an advisor for Tendel Therapies and OmniScope, outside the submitted work. M.N.-J. is co-founder and shareholder of Nano1Health SL, outside the scope of the submitted work. I.M. is a shareholder of, and acts as a consultant to, AELIX Therapeutics SL. He is also the CMO of Orion Biotechnology, outside the scope of the submitted work. J.M. has received research funding, consultancy fees and lecture sponsorships from, and has served on advisory boards for, various laboratories (MSD, Abbvie, Boehringer Ingelheim, Gilead Sciences, Viiv Healthcare, Janssen-Cilag and Bristol-Myers-Squibb). The remaining authors declare no competing interests.
